Addressing the heart‑disease risk that today’s drugs leave behind Even with medication, millions remain at risk for cardiovascular events. This innovation points toward a new class of therapies that address the full range of harmful blood lipoproteins—opening more complete and durable protection for patients underserved by today’s standard treatments.

Stopping Respiratory Infections Before They Take Hold This intranasal platform reimagines antiviral protection by acting at the body’s front line—where respiratory viruses begin infection. By anchoring protection directly to airway cells, it enables longer‑lasting defense and a flexible approach that can be rapidly adapted to new and emerging viral threats.